蛛网膜下腔出血患者急性头痛管理:国际医护人员调查
该国际横断面研究通过37题网络问卷于2021年11月至2022年1月调查五个重症与神经重症相关学会成员,评估SAH头痛管理实践。516名受访者中66%来自北美、24%来自欧洲;87%认为头痛是SAH主要管理问题。住院期间镇痛主要由重症监护团队负责(57%),出院时转由神经外科负责(47%)。最常用药物为对乙酰氨基酚(90%)、阿片类(66%)、皮质类固醇(28%)和抗癫痫药(28%);39%认为阿片类或含阿片类组合最有效,22%认为皮质类固醇或含皮质类固醇组合最有效。多数提供者(69%)未因阿片危机改变阿片处方,洲际与提供者间存在差异,作者认为亟需新治疗策略和处方协调。
要点
- 住院期间SAH镇痛主要由重症监护团队负责(249/435,57%),出院时责任转至神经外科(233/501,47%)。
- 最常用药物为对乙酰氨基酚(90%)、阿片类(66%)、皮质类固醇(28%)、抗癫痫药(28%)。
- 39%(169/433)认为阿片类或含阿片类组合最有效(以重症医师为主),22%(96/433)认为皮质类固醇或含皮质类固醇组合最有效(以神经科医师为主)。
- 住院期间阿片类处方在重症医师、管理SAH患者数量更多的提供者及欧洲显著更多;出院时阿片类处方在北美更常见。
- 69%(299/435)的提供者表示阿片危机未改变其阿片处方实践。
适用人群与场景
- 治疗蛛网膜下腔出血患者的临床医生,来自五个与重症和神经重症相关的专业学会成员,国际横断面调查覆盖北美(329/497,66%)和欧洲(121/497,24%)等地。
处置流程与药物剂量
- 指南推荐使用对乙酰氨基酚和阿片类治疗SAH后头痛;调查中最常用药物为对乙酰氨基酚(90%)、阿片类(66%)、皮质类固醇(28%)、抗癫痫药(28%)。
- 住院期间镇痛主要由重症监护团队负责(249/435,57%),出院时责任转至神经外科(233/501,47%)。
- 出院时最常用药物为对乙酰氨基酚(303/381,80%),其次为阿片类(175/381,46%)和抗癫痫药(173/381,45%)。
研究设计与关键结果
- 研究类型:国际横断面研究,通过37题网络问卷于2021年11月至2022年1月发放给五个相关专业学会成员;516名受访者,497名中329名(66%)来自北美、121名(24%)来自欧洲;采用描述性分析和Fisher精确检验。
- 435名受访者中379名(87%)报告头痛是SAH患者的主要管理问题。
- 住院期间阿片类处方在重症医师、管理SAH患者数量更多的提供者及欧洲显著更多;出院时阿片类处方在北美更常见。
- 69%(299/435)的受访者表示阿片危机未改变其阿片处方实践。
证据类型、等级与局限
- 证据类型:国际横断面调查(描述性分析,Fisher精确检验);原文未报告证据等级。
- 局限:原文未报告局限性。
对床旁实践的改变
- 调查显示SAH后头痛在重症监护中是主要临床问题,镇痛在用药和疗效感知上均高度依赖阿片类;尽管阿片类有显著缺点,多数提供者未报告改变阿片处方模式。
- 作者认为亟需新的治疗策略以及提供者之间处方的协调。
指南或共识出处
- 指南推荐使用对乙酰氨基酚和阿片类治疗SAH后头痛(原文未注明具体指南名称)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Severe headaches are common after subarachnoid hemorrhage. Guidelines recommend treatment with acetaminophen and opioids, but patient data show that headaches often persist despite multimodal treatment approaches. Considering an overall slim body of data for a common complaint affecting patients with SAH during their intensive care stay, we set out to assess practice patterns in headache management among clinicians who treat patients with SAH.
METHODS: We conducted an international cross-sectional study through a 37-question Web-based survey distributed to members of five professional societies relevant to intensive and neurocritical care from November 2021 to January 2022. Responses were characterized through descriptive analyses. Fisher's exact test was used to test associations.
RESULTS: Of 516 respondents, 329 of 497 (66%) were from North America and 121 of 497 (24%) from Europe. Of 435 respondents, 379 (87%) reported headache as a major management concern for patients with SAH. Intensive care teams were primarily responsible for analgesia during hospitalization (249 of 435, 57%), whereas responsibility shifted to neurosurgery at discharge (233 of 501, 47%). Most used medications were acetaminophen (90%), opioids (66%), corticosteroids (28%), and antiseizure medications (28%). Opioids or medication combinations including opioids were most frequently perceived as most effective by 169 of 433 respondents (39%, predominantly intensivists), followed by corticosteroids or combinations with corticosteroids (96 of 433, 22%, predominantly neurologists). Of medications prescribed at discharge, acetaminophen was most common (303 of 381, 80%), followed by opioids (175 of 381, 46%) and antiseizure medications (173 of 381, 45%). Opioids during hospitalization were significantly more prescribed by intensivists, by providers managing higher numbers of patients with SAH, and in Europe. At discharge, opioids were more frequently prescribed in North America. Of 435 respondents, 299 (69%) indicated no change in prescription practice of opioids with the opioid crisis. Additional differences in prescription patterns between continents and providers and while inpatient versus at discharge were found.
CONCLUSIONS: Post-SAH headache in the intensive care setting is a major clinical concern. Analgesia heavily relies on opioids both in use and in perception of efficacy, with no reported change in prescription patterns for opioids for most providers despite the significant drawbacks of opioids. Responsibility for analgesia shifts between hospitalization and discharge. International and provider-related differences are evident. Novel treatment strategies and alignment of prescription between providers are urgently needed.
参考来源
- Maciel CB, Barlow B, Lucke-Wold B, et al. Acute Headache Management for Patients with Subarachnoid Hemorrhage: An International Survey of Health Care Providers. Neurocrit Care. 2022. PMID: 35915347. doi:10.1007/s12028-022-01571-7
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。